leisure time -WSS

leisure time

author：hotspot 2025-09-06 03:54:19 - browse：15

Rachel Haurwitz of Caribou Biosciences — Rachel Haurwitz, CEO of Caribou Biosciences. Elizabeth D. Herman for STAT

Caribou Biosciences said Thursday that its off-the-shelf CAR-T therapy induced durable, complete remissions in patients with advanced B-cell lymphoma that move it closer to the benchmarks set by more established, patient-specific CAR-T therapies.

In an update to an early-stage study, 44% of the 16 patients treated with Caribou’s on-demand therapy, called CB-010, achieved a complete remission lasting a minimum of six months — a key threshold of durability.

The CB-010 result is still preliminary, but it begins to compare favorably to currently approved CAR-T therapies, which must be custom made for each patient and have shown durable remission rates in the range of 36-40%, said Caribou CEO Rachel Haurwitz.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Do digital therapeutics have a future in medicine?

WSS

Criminal prosecution for violating HIPAA: an emerging threat

Second House panel advances two

Military medical care influenced by rank and race, new study finds

Even great ERs can’t make up for American health disparities

The lessons of Aduhelm, an Alzheimer's drug that was not to be

Military medical care influenced by rank and race, new study finds

hotspot

leisure time

explore

State Dept. review finds Biden bears some blame for Afghanistan failures

Solving academic medical centers' existential crisis

Heart attack and stroke risk calculators need revising

Addiction experts warn against a second 'war on drugs'

Medicare proposal to cover medical devices draws a mixed reaction

Big Tobacco's 'harm reduction': Is it for real, or a sham?

Apple is now the first public company to be valued at $3 trillion

Cognito secures funding to test medical device for Alzheimer's

Hepatitis C has a cure — but many Americans still lack access to it

SAMSHA loosens regulations on methadone treatment centers

leisure time

In a test for AI, buzzy startup Insitro inks drug discovery deal with Gilead

Criminal prosecution for violating HIPAA: an emerging threat

NVIDIA and Google execs on the future of AI and drug discovery

Commercial surrogacy can be ethical, despite pope’s claims

The lessons of Aduhelm, an Alzheimer's drug that was not to be

Bird flu: Don't repeat Covid's 'health versus the economy' framing

hotspot

knowledge

focus

hotspot